The FDA has approved a new type of drug, an alpha-2A adrenergic receptor agonist, to treat ADHD in children as young as six.
The Food and Drug Administration (FDA) has approved a new type of drug, an alpha-2A adrenergic receptor agonist, to treat attention-deficit hyperactivity disorder (ADHD) in children as young as six.
The new ADHD drug, gunafacine (Intuniv), is from Shire Pharmaceuticals. The approval is for children ages 6 to 17 years of age. It will come in four dosage strengths, 1, 2, 3, and 4 mg, and is a nonscheduled medication. Its common adverse events include somnolence, headache, fatigue, upper abdominal pain, and sedation.
FDA also approved two treatments for less common maladies. For cytomegalovirus in pediatric kidney and heart transplant recipients, it approved the antiviral valganciclovir hydrochloride (Valcyte) from Roche. And for children ages 1 to 12 with cystic fibrosis, it approved pancrelipase (Zenpop), a pancreatic enzyme product made by Eurand NV.
Exome sequencing should be used for diagnosing cerebral palsy
October 13th 2023A systematic review and meta-analysis found that such sequencing indeed has an equivalent high genetic diagnostic yield in cerebral palsy, which supports including this neurodevelopmental disorder among those for which diagnostic exome sequencing should be used.
Is ADHD associated with shorter-than-expected height?
October 10th 2023To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.
Associations between prenatal metal mixture exposure and negative infant outcomes
September 19th 2023Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.